Low dose oral contraceptives with less breakthrough bleeding and sustained efficacy
US5552394A · kind A · utility
35Cited by
4References
12Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Jul 22, 1994 |
| Grant date | Sep 3, 1996 |
| Priority date | — |
| Expiry date | Jul 22, 2014 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/567
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method of female contraception which is characterized by a reduced incidence of breakthrough bleeding after the first cycle involves monophasicly administering a combination of estrogen and progestin for 23-25 consecutive days of a 28 day cycle in which the daily amounts of estrogen and progestin are equivalent to about 5-35 mcg of ethinyl estradiol and about 0.025 to 10 mg of norethindrone acetate, respectively and in which the weight ratio of estrogen to progestin is at least 1:45 calculated as ethinyl estradiol to norethindrone acetate.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.